Palisade Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Palisade Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-67,756	Closed	-$3.43M	–	510
2016 Q3	$3.43M	Sell	67,756 -20,882	-24%	-$1.04M	0.12%	225
2016 Q2	$4.03M	Sell	88,638 -56,524	-39%	-$2.6M	0.15%	203
2016 Q1	$5.74M	Sell	145,162 -61,455	-30%	-$2.44M	0.19%	171
2015 Q4	$11.7M	Sell	206,617 -30,041	-13%	-$1.53M	0.38%	78
2015 Q3	$9.42M	Buy	236,658 +101,804	+75%	+$4.92M	0.28%	130
2015 Q2	$6.44M	Buy	+134,854	New	+$5.72M	0.16%	216

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Palisade Capital Management's NBIX Position: Q4 2016 in Review

Palisade Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2016, closing a stake of 67,756 shares — an estimated $3.43M sold.

Palisade Capital Management first reported a position in NBIX in Q2 2015 and held it in 6 quarters. The position peaked at $11.7M in Q4 2015. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

Palisade Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2016 after selling out during the quarter.
Palisade Capital Management sold 67,756 Neurocrine Biosciences shares in Q4 2016, an estimated $3.43M.
Palisade Capital Management first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 6 quarters.
Palisade Capital Management's Neurocrine Biosciences position peaked at $11.7M in Q4 2015.
225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on Palisade Capital Management's 13F filing for Q4 2016, filed 31 Jan 2017.